101 GenAI Company Profile

Background

101 GenAI is a pioneering company dedicated to empowering health-tech entrepreneurs by integrating generative artificial intelligence (GenAI) into healthcare workflows. The company's mission is to enhance healthcare accessibility and efficiency through innovative AI solutions, enabling seamless integration of GenAI into healthcare products, akin to embedding payment systems. Operating within the software development industry, 101 GenAI focuses on building, deploying, and scaling multimodal AI co-pilots that integrate with existing healthcare products via APIs.

Key Strategic Focus

101 GenAI's strategic focus centers on developing healthcare-specific AI platforms that facilitate the creation of multi-agent workflows with API integrations. This approach allows for rapid development, deployment, and scaling of AI solutions within healthcare settings. The company specializes in providing tools for building, launching, and scaling healthcare co-pilots, enhancing clinical decision support, administrative processes, patient engagement, clinical trials, drug discovery, and medical imaging. By offering customizable pre-built co-pilots and access to leading large language models (LLMs), 101 GenAI targets health tech companies and health systems aiming to infuse AI into their operations.

Financials and Funding

As of July 2025, specific details regarding 101 GenAI's funding history, total funds raised, and notable investors have not been publicly disclosed. The company remains privately held, focusing on expanding its platform and services within the healthcare AI sector.

Pipeline Development

101 GenAI offers a structured program titled "101 Days with 101 GenAI," guiding clients from concept to customer deployment within a defined timeline:

Explore (Within 30 days): Clients can customize pre-built co-pilots, select from leading LLMs, enhance co-pilots with their knowledge base, access public healthcare datasets, and integrate via APIs.

Build (Within 60 days): This phase includes all features from the Explore phase, plus options to choose from large vision models, connect to private datasets, involve in-house experts, personalize with user context, and receive increased query credits.

Launch (Within 101 days): Encompassing all previous features, this phase adds capabilities like audio input/output, doctor-in-loop integration, deployment of a network of co-pilots, fine-tuning with reinforcement learning from human feedback (RLHF) or direct preference optimization (DPO), and model assessment with evaluation frameworks.

Scale (After 101 days): Post-launch, clients can customize open-source models, integrate electronic health record (EHR) data, incorporate Apple/Google health data, support longitudinal data, deploy in their virtual private cloud (VPC), and receive higher query credits or bring their own key (BYOK).

This structured approach ensures rapid development and deployment of AI solutions tailored to healthcare needs.

Technological Platform and Innovation

101 GenAI distinguishes itself through its proprietary healthcare-specific AI platform designed to build multi-agent workflows with API integrations. Key technological innovations include:

Proprietary Technologies: The platform enables the creation of multimodal AI co-pilots that can be customized and integrated into existing healthcare systems, facilitating tasks such as clinical decision support, administrative automation, and patient engagement.

Scientific Methodologies: Utilizing advanced machine learning algorithms, including LLMs and large vision models, the platform supports the development of AI solutions that can process and analyze complex healthcare data.

AI-Driven Capabilities: The platform offers features like Retrieval-Augmented Generation (RAG) and turnkey EHR integrations, driving clinical, operational, and financial impact securely and at scale.

Leadership Team

101 GenAI's leadership comprises experienced professionals with diverse backgrounds:

Janardan Prasad, Chief Executive Officer: An IIT Kanpur graduate, Janardan has built multiple 0-to-1 products, including self-serve life sciences analytics at Lore IO, a data preparation startup acquired by Alteryx. At Alteryx, he led product innovation and growth. His work has been recognized by The New York Times, Harvard Business Review, Forbes, Gartner, and Fast Company, which named him one of the "100 Most Creative People in Business" in 2015.

Prashanth Susarla, Chief Technical Officer: With 20 years of experience in software engineering and technology leadership, Prashanth played a pivotal role in propelling PayU Payments (India) to market leadership and profitability. He holds a B.Tech in Computer Science from IIT Kanpur, an MS in Computer Science (Machine Learning) from Georgia Tech, and an MBA from the Indian School of Business.

Praveen Dua, Director of Product Engineering: An accomplished product and technology leader, Praveen has a track record of building and launching innovative products. He graduated from IIT Kanpur and earned a PhD from the University of Illinois at Urbana-Champaign. Throughout his career at Qualcomm, Atheros, Lore IO, and Alteryx, he has been granted 24 patents.

Namrata Rastogi, Chief Medical Officer: With over 15 years of healthcare industry experience across three continents, Namrata has led transformations in startups, health systems, and big tech. She has served as a Health Advisory Board Member at Palantir Technologies and Health Investment Advisor at Backed VC. Namrata is an experienced clinician, product advisor, and startup mentor.

Leadership Changes

As of July 2025, there have been no publicly disclosed significant changes or appointments within 101 GenAI's leadership team.

Competitor Profile

Market Insights and Dynamics

The generative AI market is experiencing rapid growth, with significant investments and advancements in AI technologies. The healthcare sector, in particular, is witnessing increased adoption of AI solutions to enhance clinical decision-making, administrative processes, patient engagement, and more. The AI-based diagnosis market is projected to grow at a compound annual growth rate (CAGR) of 48.6% from 2022 to 2030.

Competitor Analysis

Key competitors in the generative AI space include:

OpenAI: Known for its advanced generative models like GPT-4, DALL-E, and Codex, OpenAI focuses on developing artificial general intelligence (AGI) that is secure and beneficial.

Anthropic: Specializing in AI safety and research, Anthropic aims to create reliable, understandable, and controllable AI systems, with products like Claude, a generative AI platform capable of producing realistic images, videos, and sounds.

Stability AI: Developer of Stable Diffusion, a versatile generative AI platform that integrates with top tools and applications, focusing on creating foundational models to enhance other generative AI projects.

Hugging Face: A community-driven platform providing a wide range of pre-trained models and datasets, facilitating AI and machine learning model development.

These companies are shaping the future of AI and its role in society through continuous innovation and strategic investments.

Strategic Collaborations and Partnerships

As of July 2025, specific details regarding 101 GenAI's strategic collaborations and partnerships have not been publicly disclosed. The company continues to focus on expanding its platform and services within the healthcare AI sector.

Operational Insights

101 GenAI differentiates itself by offering a healthcare-specific AI platform that enables rapid development and deployment of AI solutions tailored to healthcare needs. The company's structured "101 Days with 101 GenAI" program provides a clear roadmap for clients to integrate AI into their workflows efficiently. By focusing on multimodal AI co-pilots and seamless API integrations, 101 GenAI addresses the unique challenges of the healthcare industry, positioning itself as a valuable partner for health tech companies and health systems.

Strategic Opportunities and Future Directions

Looking ahead, 101 GenAI is poised to capitalize on the growing demand for AI solutions in healthcare. Potential opportunities include:

Expansion of AI Co-Pilot Applications: Developing new co-pilots to address emerging healthcare challenges and expanding the range of supported use cases.

Enhanced Integration Capabilities: Strengthening API integrations with existing healthcare systems, including EHRs and other health data platforms, to facilitate seamless adoption.

Strategic Partnerships: Forming alliances with healthcare providers, payers, and life sciences organizations to co-develop AI solutions and expand market reach.

Global Expansion: Exploring opportunities to offer services in international markets, adapting solutions to meet diverse healthcare needs and regulatory environments.

By leveraging its current strengths and focusing on these strategic areas, 101 GenAI aims to drive innovation and growth in the healthcare AI sector.